Document Detail


Evidence of residual ischaemia: real danger or myth?
MedLine Citation:
PMID:  7621315     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The extent and severity of residual myocardial ischaemia are well-known as major determinants of mortality after myocardial infarction, and non-invasive assessment of these parameters still plays a critical role in the management of patients. Most of the published data on this topic derive from observations collected before the widespread use of thrombolysis. The results of large multicentre trials assessing the most appropriate therapies after thrombolysis have shown that the more conservative strategy of reserving catheterization and revascularization for patients with recurrent spontaneous or induced ischaemia may be the best approach. Sophisticated techniques to detect more accurately the residual ischaemic burden after infarction have been suggested that would have a major impact on clinical decision making and on the cost of health care. The relative influence of residual ischaemic on the prognosis after myocardial infarction, however, has recently been questioned. The relative risk associated with residual ischaemia seems to be low compared with other predictors of mortality. The progression of coronary artery disease is variable and highly unpredictable, and this may be a major limitation of our ability to predict further ischaemic events.
Authors:
A Giordano; M Galli; C Marcassa
Related Documents :
7759715 - Deletion-type allele of the angiotensin-converting enzyme gene is associated with progr...
3873155 - High-dose intravenous thrombolytic therapy in acute myocardial infarction: efficiency, ...
21098445 - Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits ...
2850185 - Recovery of left ventricular function after myocardial infarction can be predicted imme...
19026315 - Geographic differences in clinical presentation, treatment, and outcomes in type a acut...
8624365 - Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing t...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of cardiovascular risk     Volume:  1     ISSN:  1350-6277     ISO Abbreviation:  J Cardiovasc Risk     Publication Date:  1994 Dec 
Date Detail:
Created Date:  1995-08-29     Completed Date:  1995-08-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9436980     Medline TA:  J Cardiovasc Risk     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  314-21     Citation Subset:  IM    
Affiliation:
Clinica del Lavoro' Foundation, IRCCS, Cardiology Division, Gussago Medical Centre, Brescia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Forecasting
Humans
Italy / epidemiology
Multicenter Studies as Topic
Myocardial Infarction / complications*,  mortality,  therapy
Myocardial Ischemia / etiology*,  therapy
Prognosis
Recurrence
Risk Factors
Thrombolytic Therapy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiac remodeling and failure after myocardial infarction.
Next Document:  Arrhythmias and the autonomic nervous system.